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onstrate that SHBG isn’t just a passive plasma carrier, but 
a molecule with significant activity in different bodily tis-
sues2-5. This article will focus on presenting the proven role 
of SHBG in certain pathophysiological states, especially 
the ones that could be influenced by the direct effects of 
SHBG when bound on SHBG-R. Consequently a use of 
SHBG as a marker in pathological states stems from its 
changing concentration due to an ascertained cause.
SHBG gene and regulation of expression
The SHBG gene is located on the short arm of chromo-
some 17 (17p13.1)6 with constant exons 2-8 and a variable 
exon 1, which can be present in six possible variations, 
altogether adding up to a sum of 13 exons7. A single SHBG 
subunit consists of 373 amino acids7,8, but is present as a 
homodimer in its full form, having two available binding 
sites for hormones9. Regarding its glycosylation, it con-
Introduction
Sex hormone binding globulin (SHBG) is a glycoprotein 
transporting steroid hormones which has the highest af-
finity for androgens, namely dihydrotestosterone (DHT) 
and testosterone, and up to five times lesser affinity for 
estrogens, thus representing the key transport vehicle for 
these sex steroids1. In addition to non-specific carriers such 
as albumin, SHBG concentration primarily regulates the 
availability of the aforementioned steroids. The postulate 
known as ‘free-hormone hypothesis’ states that the ‘bio-
available’ hormone, i.e. the one having an effect when it 
binds to its receptor, is the unbound or ‘free’ fraction of the 
hormone1. However, new experimental evidence have prov-
en that SHBG itself can elicit a response by binding to its 
respective receptor2,3, as well as change the usual response 
to the steroid hormone on the target cell, depending on 
whether it was bound before or binds after SHBG already 
reached its own receptor (SHBG-R)2-5. These findings dem-
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Sex hormone binding globulin (SHBG) is an important protein, not only for transporting sex steroids which is its 
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tains one O-linked and two N-linked oligosaccharide 
chains10,11 as well as a possible third N-glycosylation site 
that arises from a mutation in exon 8 and provides an ad-
ditional property of having a reduced clearance rate12. The 
human tissues in which transcription of the SHBG gene 
occurs are: testis, liver, breast, brain, endometrium, ova-
ries, prostate3,7,13. Besides these sources, for research pur-
poses, cancer cell lines from prostate, breast and liver 
tissue are used, as well as transgenic mice expressing a 
human SHBG transgene7,14. Single nucleotide polymor-
phisms in the SHBG gene which have a measurable effect 
on plasma SHBG concentration exist. The reference se-
quence (rs) 6257 being CC or CT instead of wild-type TT, 
resulted in a 10% decrease in the SHBG level, while rs 
6259 being AA or AG resulted in a 10% increase in plasma 
SHBG15. A protein named hepatic nuclear factor 4 alpha 
(HNF-4α), is a key factor that increases SHBG expres-
sion16,17, while the chicken ovalbumin upstream promoter-
transcription factor (COUP-TF) decreases it17 as well as 
peroxisome proliferator-activated receptor gamma 
(PPARγ)18. On the molecular level, factors that increase 
HNF-4α gene expression are thyroid hormones19, estro-
gens16, AMPK and β-oxydation induced by adiponectin 
receptor activation20,21. On the other hand, molecular cas-
cades that decrease HNF-4α gene expression are medi-
ated by NFκB22 and c-Jun, raised by activation of TNFα22,23 
receptor and IL-1β receptor24 respectively. High carbohy-
drate diet that promotes lipogenesis and lowers β-oxidation 
also inhibits HNF-4α gene expression4,25. PPARγ produc-
tion is inhibited by oleate4,26 via lowering its genetic ex-
pression and this has been reported on a ‘macroscopic 
level’ in clinical data through correlation of olive oil intake 
and increased SHBG levels26.
Central and Peripheral Roles and Effects of 
SHBG
When discussing SHBG, most of the research is done 
in context of a assessing its concentration in blood or pe-
ripheral tissues, while the aspect from central regulation, 
i.e brain is an entirely different topic rarely mentioned. It 
would be valuable to consider the role of neurosteroids27 in 
terms of the brain as the generator of behavior and thusly 
being involved in various pathological states that are 
linked with changed levels of SHBG and peripheral hor-
monal dysfunction, but also not omitting a vice versa ef-
fect4,5,13. SHBG has been confirmed to exist in human 
hypothalamus, median eminence and infundibulum, 
namely in the perikarya of neurons, nerve fibers and ep-
endymal cells, but not in the nuclei13. Since SHBG region-
al expression was co-localized with neurons expressing 
oxytocin, it has been proposed that brain produced SHBG 
is also sent through axonal transport to the posterior pi-
tuitary13. Through measuring molecular weights, a 53-
kDa and a 49-kDa SHBG protein was noted, the heavier 
found in serum and the other in cerebrospinal fluid (CSF). 
The lighter SHBG protein was also found to be the one 
produced in the hypothalamus leading to the proposition 
that the CSF levels of SHBG protein are of brain origin13. 
Substantial evidence confirm that peripherally produced 
sex hormones end up in the brain, but are differently tak-
en up by neurons depending on the sex hormone type and 
receptors expressed13,28,29. The decreases in hormone pro-
duction has been linked with symptoms of brain aging and 
declining cognitive performance including Alzhemier dis-
ease5,30. Glial cells in the brain also represent major tar-
gets for sex hormones which results in indirect effect on 
neurons31. This demonstrates the importance of sex hor-
mones for brain health and since SHBG is directly in-
volved in sex hormone transport, changes in one’s hor-
monal and SHBG status tones the behavior and mood on 
account of those being the results of neuronal output.
Peripheral organ that is the main producer of SHBG is 
the liver1-3. Androgens and estrogen may be carried either 
by SHBG or albumin, or remain unbound as the tradition-
ally known ‘free’ fraction1. In regards to liver’s prominent 
role in whole body metabolism, any primary or secondary 
hepatic pathological state that affects it significantly will 
express as a deviation of SHBG levels and consequentially 
sex hormone imbalance. It should be also kept in mind that 
sex differences make a considerable difference when deal-
ing in topics regarding SHBG. Even though the prepuber-
tal SHBG concentrations are similar in both sexes32, in 
adult population, the female levels are as twice as high as 
the male32. In senescence however, male SHBG levels tend 
to increase by 1.1% yearly32,33 and female tend to drop32. 
The cellular mechanisms which can represent a few ‘final 
common molecular pathways’ have already been discussed 
and due to different etiologies and pathogeneses for certain 
organ systems on a grander scale, all associated with vari-
able SHBG levels, a separate explanation is warranted.
Uses of SHBG in Various Pathophysiological 
States
Nutritional status
SHBG serum levels are higher in individuals suffering 
from anorexia nervosa34-37. It was found that in those in-
dividuals, SHBG levels were inversely correlated with 
weight gain and no correlation was observed in relation to 
the hormonal status, namely levels of gonadotropins, es-
trogen, testosterone, triiodothyronine36,37. Restoring body 
mass in anorexic individuals was followed by a decrease 
in SHBG serum levels34,36,37. Interestingly, high SHBG 
levels have been confirmed in pathological states of an-
orexia nervosa and kwashiorkor, while not in marasmus35. 
After measuring inflammation with C-reactive protein as 
a marker, and glomerular filtration through cystatin-C, 
the same conclusion was still reached for marantic pa-
tients, since these two markers used haven’t shown cor-
relation with SHBG levels35. As follows, SHBG represents 
a reliable value in assessment of refeeding in diseases 
such as anorexia nervosa34-37 and kwashiorkor, but not in 
marantic state35. In the latter case SHBG can be used to 
differentiate it from the aforementioned diseases35.
Obesity is linked with lover serum levels of SHBG in 
both men38 and women39. Even after adjustment for an 
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age-linked increase in men, the levels of SHBG still de-
clined when obesity was present. In child population, obe-
sity and chronic inflammation lowered SHBG levels40, 
which anticipated earlier puberty onset – a more common 
feature in present time41-43. Estrogen and androgen levels 
change accordingly to the ‘free hormone hypothesis’, which 
means a larger fraction of unbound hormone is ‘bio-avail-
able’ to exert its effect that is clinically noticeable. With 
the arising future clarification for the role of SHBG as an 
active protein in cellular signalization more details about 
the physiology of puberty onset are destined to come.
Metabolic syndrome
Metabolic syndrome (MetS) is a cluster of features that 
shows a general dysfunction of the physiology of cellular 
metabolism. It is linked with central obesity and insulin 
resistance as the etiological factors44,45. The criteria for a 
clinical diagnosis also include hypertension and dyslipid-
emia46. The affection of the liver as the main metabolism-
regulating organ has profound pathophysiological conse-
quences. Liver steatosis or non-alcoholic fatty liver disease 
(NAFLD) is a common feature in metabolic syndrome and 
the leading etiology for liver dysfunction47. The state of 
metabolic syndrome is a vicious circle where hyperglyce-
mia and dyslipidemia are aggravated with increasing in-
sulin resistance and liver fat accumulation. This ultimate-
ly leads to chronic inflammation46, 48-50 with lower levels of 
anti-inflammatory cytokines (e.g. adiponectin) and higher 
levels of proinflammatory cytokines (IL-1, IL-6)4. Conse-
quently, unfavorable signaling cascades are triggered in 
hepatocytes. Regarding the role of the liver in the produc-
tion of SHBG, the levels of this protein drop significantly 
in individuals with MetS39,51,52 and SHBG levels can even 
serve as a predictive value for pubertal children develop-
ing metabolic syndrome and obesity in adulthood53. The 
role of SHBG for being a sensitive biomarker for MetS 
comes from the evidence that monosaccharide induced li-
pogenesis, especially with higher fructose intake, regu-
lates the expression of SHBG gene in the liver16,54 and 
decreases the hepatic production of SHBG. Weight loss is 
followed by an increase in SHBG serum levels. In post-
menopausal women with visceral obesity, a greater de-
crease in leptin concentrations was linked with lower ini-
tial SHBG concentration preceding a weight loss, 
independent of total amount of weight lost55. Weight reduc-
tion in peripubertal obese children was followed by an 
increase in SHBG concentrations and more favorable aris-
ing pubertal traits56 (virilization in males and less viril-
izing in females). In adult obese male population, SHBG 
levels increased and were correlated with weight loss as 
well as the general reproductive health features, i.e. sperm 
count, semen volume and testosterone levels57. In obese 
patients, SHBG levels serve as an indicator of total adipos-
ity, rather than disrupted insulin regulation58. MetS is 
linked with a combined pathophysiology of Type 2 Diabe-
tes (T2D) and cardiovascular disease (CVD) and is associ-
ated with a higher risk for developing both of these in an 
affected individual46.
Cardiovascular risk
Cardiovascular risk is different sex-wise, with the 
male population being at a greater risk, while women en-
joy the cardioprotective role of estrogens59,60 up until 
reaching postmenopause when these risks are believed to 
be equalized. Even though, recent evidence support that 
by maintaining normal testosterone levels in men, a car-
dioprotective effect is exhibited61. Both estrogens and an-
drogens are transported primarily by SHBG, so obviously 
the changing levels of serum SHBG must have an impor-
tant role in predicting the cardiovascular risk, according 
to sex, age and hormonal status of the individual. In the 
renowned Framingham score, total cholesterol and HDL 
cholesterol are important contributors to total calculated 
cardiovascular risk62. For SHBG, it has been shown to be 
positively correlated with HDL levels, and inversely with 
insulin and triglycerides63. Even more intriguing is that 
the HDL uptake via its receptor seems to be involved in 
SHBG cellular uptake in in steroidogenic cells5. Whether 
SHBG is needed in steroid synthesis since HDL repre-
sents a steroid precursor still remains unresolved. All in 
all, low SHBG concentrations seem to be associated with 
a worse cardiovascular state through promoting the im-
balance of usually bound hormones and by generally low-
er activation of HDL receptor stemming from low blood 
HDL concentration. Since the risk for cardiovascular dis-
ease is higher in individuals suffering from MetS44,46,47, in 
which SHBG has been shown to be lowered, a joint patho-
physiological process combines these diseases. It has been 
demonstrated in a 12-year long follow up that a decrease 
in SHBG represents a significant risk factor in overall 
mortality64,65. SHBG stands as an available marker for 
assessment of cardiovascular health, especially in female 
population66. Future implications might be even broader 
regarding cardiovascular risk assessment and the impor-
tance of SHBG in cardiovascular pathophysiology, since 
this protein is produced by cardiomycocytes in patients 
suffering from dilated cardiomyopathy and appears to be 
internalized by them possibly representing a mechanism 
for delivering sex hormones to heart muscle2.
Breast, prostate, ovarian and endometrial 
cancer
The pathophysiological role of SHBG and its receptor 
is particularly important in terms of studying how breast 
cancer cells behave in relation to estrogen and SHBG lev-
els. When SHBG is bound to its receptor on an estrogen-
dependent breast cancer cell and when estrogen binding 
subsequently follows, an increase in cellular cyclic adenos-
ine monophosphate is noted and Protein kinase A is acti-
vated3. This could indicate that SHBG-R is a G-protein 
membrane receptor. Further signalizing possibly through 
MAP kinase pathway isn’t elucidated, but by modifying 
cellular behavior, a clear inhibition of usual proliferative 
estrogenic effect on breast cancer cells is seen, however 
only if SHBG binds to its receptor prior to binding with 
estrogen67. Estrogen-positive breast cancer cells bind 
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SHBG twice as often as estrogen-negative cells, where 
only an average of 37% of breast cancer cells bind this 
particular glycoprotein3,67. Another mechanism for cancer 
protection involves the mere binding by SHBG of other-
wise ‘free’ estrogen, which lowers estrogen levels that 
could potentiate growth in breast cancer cells. The ‘free 
hormone hypothesis’ is definitely updated in oncology by 
provided evidence that not only the hormone levels, but its 
binding proteins also, have an impact on cancerous 
growth. A meta-analysis from 201568 showed that SHBG 
levels are significantly associated with a lower breast can-
cer risk, moreover being a protective factor for developing 
this disease. In a randomized trial69, application of low 
dose tamoxifen has been linked with increased SHBG se-
rum levels and followed by a decreased risk for developing 
breast cancer. Weight loss which lowers estrogen produc-
tion by reducing the size of a secondary endocrine organ, 
the white adipose tissue, and which increases overall 
SHBG levels has a positive effect in secondary prevention 
of breast cancer, i.e. recurrence or poorer prognosis70.
In the prostate, the binding of estrogen to the already 
receptor bound SHBG induced PSA production, an effect 
which could be blocked by antiandrogens and not anti-es-
trogens3. It suggests that the same signalization as in 
breast cancer cells has a different final effect, i.e. it doesn’t 
exert an anti-proliferative effect. In vitro and pathological 
analyses provide findings that support the correlation be-
tween SHBG expression in prostate tissue and more ad-
vanced cancerous features, be it microscopically or in 
terms of general disease progression71. SHBG after radical 
prostatectomy, as a predictive factor for biochemical cancer 
recurrence, improves predictive accuracy72. On the con-
trary, in men without prostate cancer, SHBG levels were 
inversely correlated with PSA concentration73. A biopsy 
cohort study74 concluded that SHBG shouldn’t be regarded 
as a predictive marker in prostate cancer, which is still 
debatable since other studies prove higher SHBG levels to 
be correlated with detection of prostate cancer75. Obesity 
has been shown to be significantly associated with prostate 
cancer stage and that low testosterone concentration is just 
a rising epiphenomenon of increased abdominal fat76. This 
might also have implications for interpretation of changing 
SHBG serum levels in this pathology. Adiposity, leading 
to liver steatosis as well as increased estrogen production, 
but coupled with the positive effects of estrogens and adi-
ponectins on SHBG expression and negative effects of dys-
regulated cellular metabolism, chronic inflammation and 
androgen status on that same gene expression evidently 
describes a complex pathophysiological process where the 
role of SHBG as a mediator in hormonal transport and 
efficacy should be investigated further.
It had only been recently that SHBG has been consid-
ered to be investigated in relation to ovarian cancer. Its 
gene expression in cancerous cells was significantly cor-
related with cancer aggressiveness77. A smaller sample 
study78 compared healthy and pathologically changed ova-
ries and concluded that premenopausal normal ovaries as 
well as cancerously changed both expressed SHBG, sug-
gesting that a kept ability of the cancer to synthesize 
SHBG might be involved in cancerous growth. In addition, 
an overexpression in exon-7-splicing-variant of SHBG 
gene has been noted in ovarian cancerous cells when com-
pared to healthy ones79. This exon is involved in coding the 
steroid binding site, so an alteration may have an impact 
in binding affinity for sex steroids, namely estrogen. The 
influence of SHBG in pathology of ovarian cancer and its 
clinical relevance still remains largely understudied.
Similarly, the connection of SHBG and endometrial 
cancer still remains to be investigated. An eight-year co-
hort study in European countries showed a correlation 
between lower SHBG plasma levels and appearance of en-
dometrial cancer, but with inflammation having the prom-
inent role in endometrial carcinogenesis80. Accordingly, 
SHBG might be substantially lowered due to ongoing in-
flammatory state. In a large gene-diet case control study, 
it has been shown that the consumption of soy and tea with 
a particular polymorphism in SHBG gene at Asp(327)/
Asn(rs 6259) that prolongs SHBG half-life, which both 
leads to higher SHBG serum levels in pre-menopausal pe-
riod and lower incidence of endometrial cancer in post-
menopause81. It is also noted that as endometrial cancer 
undergoes de-differentiation, the levels of SHBG expres-
sion in endometrial cells decreases82 accompanied by exon-
7-splicing-variant increase83. Insofar, there isn’t a clinical 
implication for SHBG as a marker in endometrial cancer 
and specifically orientated research is still scarce.
Insulin resistance in women and link with 
polycystic ovary syndrome (PCOS)
Insulin resistance is a common state associated with 
diseases already mentioned and strongly proven by sys-
temic meta-analyses, these include obesity with predomi-
nant visceral fat84, increased cardiovascular risk85, endo-
metrial cancer86 and metabolic syndrome in which the 
presence of hyperglycemia is an including factor46 for defi-
nition. Insulin resistance is also linked to polycystic ovary 
syndrome87 and which is especially interesting from the 
view of assessing the role of SHBG as a mediator between 
the metabolism and hormonal status, i.e. reproductive 
health. With higher level of blood glucose, hepatic lipogen-
esis is promoted and a downregulation of HNF-4α follows, 
ultimately leading to lower production of SHBG54. Insulin 
does not in itself lower the hepatic production of SHBG54 
as was previously concluded in a common cited study for 
this claim88, but it acts as a co-gonadotropic factor on the 
ovary exerting a negative effect on hormonal balance and 
signaling89. A hallmark of PCOS is androgenicity, which 
only aggravates the glucose regulation and also lowers the 
SHBG production thus having a double negative effect on 
the whole pathophysiological process by further promoting 
unfavorable metabolic changes and hormonal imbalance. 
When adiposity as a feature of metabolic syndrome is also 
co-present with PCOS, a state of chronic inflammation is 
also maintained and which further perpetuates the patho-
physiological process of lowering SHBG levels and induc-
ing other pathological process happening in PCOS. This is 
backed up by a meta-analysis showing connection of IL-6 
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levels and PCOS90. Treatments that include weight loss 
lowering insulin resistance through lifestyle modifica-
tion91,92 and combined with pharmacological treatment 
such as prescribing metformin92, prove to be a successful 
approach in PCOS. Metformin alone or in combination 
with statins does alter the lipid profile and inflammation 
towards a more desirable status, but insulin sensitivity 
and hyperandrognicity doesn’t reach a desirable therapeu-
tic target93, even though metformin induces a decrease of 
LH-stimulated testosterone response of the ovaries94. Oral 
contraception, which is also used in treating PCOS to 
regulate menstrual cycles and reduce androegnicity, rais-
es HDL levels, but doesn’t have a uniform effect regarding 
glucoregulation95. Exercise on its own has pleiotropic ef-
fects and is beneficial for women suffering from PCOS, 
since evidence exist that it produces positive changes in the 
metabolic profile96, even when body weight doesn’t de-
crease. Serum SHBG levels increase after lifestyle modi-
fication97 in PCOS affected women.. The interrelations 
amid the different endocrine tissues are definitely empha-
sized in PCOS, mainly the gonads and the liver with pe-
ripheral metabolism-regulating tissues being the promi-
nent ‘headliners’. Sex hormones, insulin, adipokines are 
signal molecules that mediate their interplay. In regards 
to all these hormones having an effect on the liver, it being 
the site of most SHBG production, serum levels of SHBG 
will change in response to the predominant metabolic/hor-
monal state in an individual. From the molecular mecha-
nisms explained earlier, comes the role of SHBG as both 
an actively involved protein in the pathophysiology, but 
being a valuable marker additionally.
Patients who responded to metformin therapy in PCOS 
had lower initial mean SHBG levels than those who did 
not98,99. In adolescent patients who had a more repeating 
TAAAA region in SHBG gene, a more beneficial effect on 
lipid profile was seen after one-year long treatment with 
metformin for PCOS100, but SHBG gene and polymor-
phisms in their own aren’t associated with PCOS in etio-
logical sense101. After adjustment for fasting insulin levels, 
fasting glucose and adipokines in mixed population, low 
SHBG remained a strong marker in women for dysregu-
lated glucose metabolism, independently of the aforemen-
tioned values and could serve as an identifying factor for 
developing diabetes102. Increased liver fat in midlife wom-
en with a higher metabolic risk showed a strong indepen-
dent connection with low SHBG levels51. In women of fer-
tile age that were in treatment for PCOS with goals of 
reaching ovulation, pregnancy and birth, increased SHBG 
and decreased free-androgen index strongly marked the 
effectiveness of the treatment103. There is even evidence 
that preconception SHBG levels in women affected with 
PCOS may be a better predictor for development of gesta-
tional diabetes mellitus than waist circumference or in-
sulin resistance (HOMA-IR)104. In a study on 180 women, 
for each increment of a single unit of nanomol per liter, 
there was a 7% reduction in the risk for development of 
gestational diabetes mellitus105.
With clarification of the exact pathophysiology and rea-
sons for the changing levels of SHBG, i.e. defining what 
is the cause and what is the consequence, surely a more 
specific role for this protein as a marker could be imple-
mented. For now, the mentioned uses might be considered 
reliable.
Osteoporosis
Bone helath is inevitably associated with sex hormones 
and thusly with SHBG as the main carrier-protein. In a 
longitudinal study on more than 6 000 women that lasted 
for almost 20 years, it was observed that lower ratio of 
androgens and SHBG correlated with osteoporotic frac-
tures106, while the opposite being true for a higher ratio. 
Elderly men have lower free testosterone and higher 
SHBG levels, which was associated with lower bone min-
eral density107 and vertebral fractures108-110, it is important 
to keep in mind the fact that male SHBG tends to increase 
with age5. Generally, higher levels of SHBG in both sexes 
were associated with greater bone resorption and lower 
bone mineral density109,111,112, predisposing one for osteo-
porotic fractures. Increased levels of unbound sex hor-
mones might be beneficial for prevention of osteoporosis113, 
suggesting that high SHBG levels in older population are 
undesirable regarding bone helath.
Conclusion
SHBG is an important protein since its involved in 
regulating sex hormone availability, but also possess an 
ability to influence the effect of the hormone when it bind 
to the receptor, the reason being the existence of SHBG-R. 
This review demonstrated the various pathophysiological 
roles of this protein, but also diseases where it can clini-
TABLE 1
SEX HORMONE BINDING GLOBULIN: AN OVERVIEW OF 
PATHOPHYSIOLOGY AND CLINICAL USES
Causes of higher serum levels 
of sex hormone binding 
globulin
Thyroid hormones
Estrogens
Adiponectins
β-oxidation in producing cells
Oleic acid intake
Causes of lower serum levels 
of sex hormone binding 
globulin
Inflammation
Fatty liver
Androgens
Current states where sex 
hormone binding globulin can 
be used as a marker
Anorexia nervosa
Obesity
Low serum HDL
Breast and prostate cancer
Gestational diabetes mellitus,
Polycystic ovary syndrome
Osteoporosis
Possible future implications 
where sex hormone binding 
globulin could be used as a 
marker
Infertility
Aging
Neurodegenerative diseases
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cally help in marking certain outcomes or present states 
in which an individual currently is. A brief overview of 
pathophysiological processes affecting SHBG levels, its 
current clinical use and possible future implications are 
represented clearly in Table 1. Future research should 
bring interesting findings, since possibilities for using 
SHBG as a marker are numerous, but it also warrants 
thorough comprehension of its physiology, an area which 
is still understudied. Additionally, possible links with the 
hormone oxytocin could yield important implications, 
while the focus is still on its primary role of binding sex 
hormones. The existence of SHBG-R also implies that the 
‘free-hormone-hypothesis’ shouldn’t be misused, and by 
investigating the physiology of these receptors, more ac-
curate and correct findings are bound to come.
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GLOBULIN KOJI VEŽE SPOLNE HORMONE (SHBG) KAO MARKER U KLINIČKIM POREMEĆAJIMA
S A Ž E T A K
Globulin koji veže spolne hormone (SHBG) je važan protein, ne samo kao primarni nosač spolnih steroida, nego se i 
otkrićem specifičnog receptora koji veže SHBG treba usvojiti novi pristup klasičnoj teoriji ‘slobodnih hormona’. Istražen 
je gen SHBG, kao i stanični mehanizmi koji utječu na njegovu ekspresiju. Značajna saznanja su dobivena i postoje dobro 
objašnjeni signalni putevi na staničnoj razini koji utječu na proizvodnju SHBG. Štoviše, pokazano je da SHBG nije samo 
periferno sintetiziran protein, već je njegovo postojanje potvrđeno i u moždanom tkivu, u području hipotalamusa i hipo-
fize. Ovdje je prostorno razmješten u bliskosti s neuronima koji proizvode oksitocin. Glavni periferni organ koji proiz-
vodi SHBG jesu jetra. Budući da su jetra središnji metabolički organ, određene metaboličke bolesti će rezultirati prom-
ijenjenom razinom SHBG u krvi. S druge strane, endokrinološki poremećaji tkiva uključenih u regulaciju spolnih 
hormona također će imati utjecaj na razinu SHBG. Stoga, SHBG stoji kao jedan od posrednika između različitih 
endokrinološki aktivnih tkiva i definitivno pridonosi svojom patofiziološkom ulogom u bolestima poput: debljine, 
metaboličkog sindroma, sindroma policističnih ovarija, osteoporoze, raka dojke i raka prostate. Njegova vrijednost prelazi 
i u područje kliničke medicine kao biljega određenih patoloških stanja. Neke studije su već utvrdile njegovu pouzdanost 
i postoji rastući trend da se uvede kao korisni biljeg u kliničkoj medicini. U pogledu patofiziologije i kliničke medicine, 
još uvijek nije dovoljno proučen, ali nedavni pronalasci daju naznake da SHBG ima važnu ulogu u zdravlju i bolesti i 
mogao bi predstavljati koristan biljeg za procjenu u kliničkoj medicini.
